ValuEngine downgraded shares of Joint (NASDAQ:JYNT) from a hold rating to a sell rating in a research report released on Thursday morning, ValuEngine reports.
Other analysts also recently issued reports about the company. TheStreet downgraded Joint from a b- rating to a c rating in a research report on Monday, January 6th. DA Davidson upped their price objective on Joint from $23.00 to $32.00 and gave the company a buy rating in a research report on Tuesday, November 12th. B. Riley restated a buy rating and issued a $25.00 price objective on shares of Joint in a research report on Friday, January 10th. Zacks Investment Research upgraded Joint from a hold rating to a strong-buy rating and set a $18.00 price objective on the stock in a research report on Tuesday, January 14th. Finally, Maxim Group restated a buy rating and issued a $25.00 price objective on shares of Joint in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $25.50.
Shares of NASDAQ:JYNT traded up $0.37 on Thursday, hitting $15.50. The company had a trading volume of 3,667 shares, compared to its average volume of 115,650. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 3.11. Joint has a 52-week low of $7.96 and a 52-week high of $21.80. The business has a 50 day moving average of $16.54 and a 200 day moving average of $18.05. The company has a market cap of $213.86 million, a PE ratio of 77.50 and a beta of 0.93.
Joint (NASDAQ:JYNT) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.01. Joint had a return on equity of 104.54% and a net margin of 6.57%. The business had revenue of $12.73 million for the quarter, compared to the consensus estimate of $11.60 million. As a group, equities analysts predict that Joint will post 0.21 EPS for the current year.
In related news, Director Glenn J. Krevlin sold 100,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $17.76, for a total value of $1,776,000.00. Following the completion of the transaction, the director now directly owns 2,500 shares in the company, valued at $44,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.10% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System increased its stake in Joint by 7.9% in the third quarter. California State Teachers Retirement System now owns 21,689 shares of the company’s stock valued at $404,000 after purchasing an additional 1,584 shares during the last quarter. Morgan Stanley increased its stake in Joint by 1,673.2% in the second quarter. Morgan Stanley now owns 183,772 shares of the company’s stock valued at $3,344,000 after purchasing an additional 173,408 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Joint by 100.7% in the third quarter. Tower Research Capital LLC TRC now owns 3,547 shares of the company’s stock valued at $66,000 after purchasing an additional 1,780 shares during the last quarter. State Street Corp increased its stake in Joint by 27.4% in the third quarter. State Street Corp now owns 245,935 shares of the company’s stock valued at $4,577,000 after purchasing an additional 52,879 shares during the last quarter. Finally, Cadence Capital Management LLC acquired a new position in Joint in the third quarter valued at $2,815,000. Hedge funds and other institutional investors own 71.39% of the company’s stock.
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.
See Also: What is an overbought condition?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.